Randomized Phase II Trial of VK2809, an Investigational Thyroid Hormone Receptor Agonist, vs Placebo in NAFLD With Hyperlipidemia

April 10-14, 2019; Vienna, Austria
Patients treated with VK2809 for 12 weeks showed significantly reduced LDL-C and liver fat content vs those treated with placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 179 KB
Released: April 22, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Learn from an expert about emerging strategies for combination treatment for NASH with GLP-1 receptor agonists plus SGLT2 inhibitors, from Clinical Care Options (CCO)

Manal F. Abdelmalek, MD, MPH Released: February 2, 2023

Experts review therapeutic interventions for NAFLD/NASH, from Clinical Care Options (CCO)

Manal F. Abdelmalek, MD, MPH
Program Director
Rohit Loomba, MD, MHSc Brent Tetri, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: 1.5 AAPA Category 1 CME Credits Released: December 7, 2022 Expired: December 6, 2023

Expert commentary on disease nomenclature based on underlying genetic factors, NASH heterogeneity, from Clinical Care Options (CCO)

Brent Tetri, MD Released: September 29, 2022

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings